Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22645326 | 0.89 | KMT2A (0.75) | KMT2ALMNATDP1POLBSMN1; SMN2 | |
| SCHEMBL12015276 | 0.89 | KMT2A (0.75) | KMT2ALMNATDP1POLBSMN1; SMN2 | |
| SCHEMBL847405 | 0.87 | TDP1 (0.76) | KMT2ALMNATDP1POLBSMN1; SMN2 | |
| SCHEMBL847416 | 0.86 | TDP1 (0.64) | KMT2ALMNATDP1POLBSMN1; SMN2 | |
| SCHEMBL7216434 | 0.75 | LMNA (0.63) | KMT2ALMNASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL8290671 | 0.75 | POLB (1.00) | KMT2ATDP1POLBSMN1; SMN2MEN1 | |
| SCHEMBL847404 | 0.74 | SMN1; SMN2 (0.57) | KMT2ALMNASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL847144 | 0.72 | KMT2A (0.49) | KMT2ALMNATDP1POLBSMN1; SMN2 | |
| SCHEMBL9691470 | 0.71 | HPGD (0.57) | KMT2ALMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL9691464 | 0.71 | HPGD (0.57) | KMT2ALMNASMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497397-B2 | Substituted acrylamide derivative and pharmaceutical composition comprising the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-30 | — | — | US | disclosed |
| US-8497397-B2 | Substituted acrylamide derivative and pharmaceutical composition comprising the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-30 | — | — | US | disclosed |
| EP-1880720-B1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2013-02-13 | — | — | EP | disclosed |
| US-20120220593-A1 | Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120220593-A1 | Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-8143446-B2 | Substituted acrylamide derivative and pharmaceutical composition comprising the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-27 | — | — | US | disclosed |
| US-8143446-B2 | Substituted acrylamide derivative and pharmaceutical composition comprising the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20090118199-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAIICHI SANKYO COMPANY , LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1880720-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118199-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ACR, NAT1, C1S | KMT2A 4205/4885LMNA 1731/4885TDP1 1470/4885 |
| US-20120220593-A1 | Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same | ACR, NAT1, C1S | KMT2A 4205/4885LMNA 1731/4885TDP1 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.